SBIR-STTR Award

Age-Dependent Single-Cell Metabolomic and Proteomic Profiling of Human Immune System
Award last edited on: 1/22/20

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$224,947
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Timothy S McConnell

Company Information

Isoplexis Inc (AKA: Isoplexis Corporation)

35 Ne Industrial Road
Branford, CT 06405
   (203) 208-4111
   info@isoplexis.com
   www.isoplexis.com
Location: Single
Congr. District: 03
County: New Haven

Phase I

Contract Number: 1R43AG066022-01
Start Date: 9/30/19    Completed: 3/31/20
Phase I year
2019
Phase I Amount
$224,947
With this phase I submission, IsoPlexis proposes to deliver comprehensive profiling of the immune system as a measure of age-dependent health in response to medical challenges or trauma. This assay will connect signaling events in the metabolome and proteome from thousands of single cells in parallel enabling the simultaneous tracking of metabolic activity and protein signaling within each immune cell type. For the purposes of improved health profiling, therapeutic targeting, and biomarkers for patient monitoring, we have received incoming demands for this novel assay from translational centers and biopharma that are focused on the aging immune system. In the normal aging process, the relative abundance of naïve T cells decreases while highly differentiated effector and memory T cells increase. Functional genetic analysis of whole blood indicates global changes in immune gene signaling as well as metabolic functioning as a consequence of age. However, deciphering these changes into meaningful impact on human health in the aging immune system requires higher resolution analyses. IsoPlexis has exclusively licensed the published, underlying metabolomics technology from our collaborator and scientific advisor Jim Heath who devised a methodology to combine detection of metabolites with proteomic profiling of intracellular signaling pathways and cytokine production in single cells. The Heath lab established uniquely combined metabolite competition capture assays with sensitive signal transduction protein capture, to help uncover unique pathways and potential treatment targets. Understanding that this development has broad human health application, cell-specific metabolic and proteomic markers as a function of age- calibrated immune system performance will guide patient response to improved personalized therapies. A new general immune health assay is needed that can (i) make highly multiplexed measurements from single cells (ii) while being able to gather both proteomic and metabolic information from the same cell (iii) in a manner that is high throughput. We propose to use this phase I grant to allow IsoPlexis to develop an integrated, automated single-cell metabolomic/proteomic platform, as a comprehensive immune health assessment to better calibrate new personalized medical treatments. Aim 1: Develop and optimize an expanded metabolite capture library on- chip and integrate with intracellular proteomic assays targeting the immune system as it matures. Aim 2: Develop methods on automated platform for monitoring single-cell metabolomic/proteomic biomarkers responding to environmental stressors to evaluate immune system metabolic resilience. Transition to phase II: To demonstrate the combined metabolomic/proteomic assay value, we will evaluate a sampling from an ethnically diverse, genetically characterized pool that our collaborators at Columbia University are collecting to advance unique metabolomic and proteomic immune profiles. Additionally, the multiplexed metabolomic/proteomic assay will be integrated onto our automated platform for commercial use.

Public Health Relevance Statement:
Aging significantly impacts the cell metabolism or energy consumption of the immune system and affects immune cells to rapidly recover from the various types of challenges. To comprehensively understand what factors are driving cell resilience in aged individuals, we aim to develop a method to measure energy consumption and effector secretion simultaneously at single cell level. Mining metabolomic information together with protein secretion, which drives cell resilience of the aging immune system will enable the development of restorative therapies in the future.

Project Terms:
Affect; Age; age related; age related neurodegeneration; aged; Aging; Automobile Driving; base; Benchmarking; Biological Assay; Biological Markers; cell type; Cells; Cellular Assay; Cellular Metabolic Process; Consumption; cross reactivity; cytokine; Cytolysis; Data; Detection; Development; Disease Progression; Elasticity; environmental stressor; ethnic diversity; Event; Flow Cytometry; Future; Genes; genetic analysis; Global Change; glucose uptake; Grant; Health; health application; health assessment; Human; Immune; immune health; Immune system; Immune Targeting; improved; Individual; Libraries; Measurement; Measures; Medical; Metabolic; Metabolic Pathway; metabolome; metabolomics; Methodology; Methods; Mining; Monitor; monocyte; normal aging; novel; Pathway interactions; patient biomarkers; Patient Monitoring; patient response; Performance; Peripheral; personalized medicine; Phase; Phenotype; Phosphoproteins; Potential Energy; Process; Production; protein metabolite; Protein Secretion; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Reporter; resilience; Resolution; response; Sampling; Signal Pathway; Signal Transduction; Signaling Protein; single cell technology; stressor; success; Surface; T memory cell; T-Lymphocyte; Technology; therapeutic target; Time; Trauma; treatment response; Universities; Whole Blood

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----